Despite promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from pharmacy benefit managers. These organizations are typically erecting obstacles to reimbursement, including steep cost requirements and approval processes that limit consumer avai… Read More